NCT Number: NCT00122941
Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda
Micronutrient deficiencies are common in HIV infected children and are aggravated by poor nutrition, especially in poor resource countries such as Uganda. It appears that micronutrient deficiencies contribute to immune dysfunction, increased morbidity and HIV disease progression. Hitherto, there has been no randomised controlled trial to assess the effect of multiple micronutrient supplementation on morbidity and mortality in HIV infected children in Africa. Therefore, the investigators shall carry out a randomised controlled trial to determine the effect of multiple micronutrient supplementation on morbidity, weight gain and mortality among HIV infected children aged 1 to 5 years in Uganda.
Hypothesis: Daily administration of twice the recommended dietary allowance (2RDA) of multiple micronutrients to HIV infected children aged one to five years, for 6 months, will reduce all cause mortality from 24% to 14.4% in one year and result in a weight gain difference of 150 grams.
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 year–5 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Centre for International Health University of Bergen, Bergen, Norway
About this study
Micronutrient deficiencies are common in HIV infected children and are aggravated by poor nutrition, especially in poor resource countries such as Uganda. It appears that micronutrient deficiencies contribute to immune dysfunction, increased morbidity and HIV disease progression. Hitherto, there has been no randomised controlled trial to assess the effect of multiple micronutrient supplementation on morbidity and mortality in HIV infected children in Africa. Therefore, the investigators shall carry out a randomised controlled trial to determine the effect of multiple micronutrient supplementation on morbidity, weight gain and mortality among HIV infected children aged 1 to 5 years in Uganda.
Hypothesis: Daily administration of twice the recommended dietary allowance (2RDA) of multiple micronutrients to HIV infected children aged one to five years, for 6 months, will reduce all cause mortality from 24% to 14.4% in one year and result in a weight gain difference of 150 grams.
A sample size of 373 was calculated assuming that the mortality risk in one year in HIV infected children is 24% (Barhane et al) and that this risk will be reduced to 14.4% in the intervention group (40% effect size) with 90% power and 95% confidence.
Assuming a 10% attrition rate (38 study participants), the final sample size in each group is 411.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Aged 1 to 5 years
- HIV infection (previously confirmed by 2 ELISAs for children > 18 months; DNA PCR for those < 18 months)
- Informed consent from the parent/caretaker
- Ability to return for follow-up (lives within a radius of 15 km from hospital and unlikely to change residence during the course of the study)
Exclusion criteria
- Children already enrolled in other studies
- Children with severe abnormalities which are likely to impair oral intake (for example, severe cerebral palsy)
- Severely ill children requiring urgent admission and resuscitation
Treatment and study plan
Primary outcomes
-
Number of children dying during the study period
-
Average weight gain in each of the treatment groups
Secondary outcomes
-
Blood micronutrient levels
-
Incidence/prevalence of diarrhoea
-
HIV disease progression (CD4 count and clinical staging)
-
Prevalence of C. parvum and E. bieneusi
-
Adverse events related to supplementation
Sponsors and collaborators
Lead sponsor
Makerere University
Other
Collaborators
- The Norwegian Programme for Development, Research and Higher Education
Registry information
Official study title
Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda: a Randomised Double Blind Placebo-Controlled Trial
Acronym: MMS
Important dates
- Study start
- 2005
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Jul 22, 2005
- Registry last updated
- Jun 16, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
NCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial DetailsA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsSafety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
NCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial DetailsSafety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
NCT02591420
Blood-Borne Infections, Communicable Diseases
Kericho, Kenya
View Trial Details